|
| Drug/bioactive molecule | Activity | Model | Enhancement of oral bioavailability | References |
|
| Candesartan cilexetil (CC) | Antihypertensive | In situ model for determining drug absorption | 2-fold increase in oral bioavailability | [125] |
| Gypenosides (GPS) | Anti-inflammatory | In situ intestinal perfusion/in vivo pharmacokinetic studies | 8.5-fold increase in bioavailability of the GPS-SGC-NLCs | [126] |
| Nimodipine (NMP) | Calcium channel blocker | In situ intestinal perfusion/in vivo pharmacokinetic studies | 161% increased bioavailability than nimodipine suspension | [127] |
| Ezetimibe (EMB) | Antihyperlipidemic | In vivo pharmacokinetic studies | 2.63-and 2.33-fold increase in oral bioavailability in comparison with EMB suspension and marketing product | [128] |
| Ritonavir (RTV) | Highly active antiretroviral therapy (HAART) | In vivo pharmacokinetic study | 2.86-fold augmentation in oral bioavailability of RTV in comparison to RTV suspension | [129] |
| Felodipine (FDP) | Antihypertensive | In vivo pharmacokinetic studies | A 2-fold oral bioavailability enhancement of FDP in comparison to marketed formulation | [130] |
| Apixaban (APX) | Anticoagulant | In vivo pharmacokinetic study | 2.67-fold increase in oral bioavailability of APX in comparison to pure drug suspension | [131] |
| Levosulpiride (LSP) | Dyspepsia | In vivo pharmacokinetic study | 4.38-fold improvement in oral bioavailability of LSP than drug dispersion | [132] |
| Amisulpride (AMS) | Antipsychotic | In vivo pharmacokinetic study | The relative bioavailability of AMS-NLCs capsules was found to be 252.78% as equated with commercial Amipride® tablets | [133] |
| Triptolide (TP) | Antiinflammatory | In vivo pharmacokinetic study | Longer residence time, sustained drug release, 1.54 times increased bioavailability than free drug | [134] |
| Ergosterol | Antidiabetic nephropathy | In vivo pharmacokinetic study | The comparative oral bioavailability of ERG-NLCs was 277.56% higher than that of pure ergosterol | [135] |
| Raloxifene (RLN) | Anticancer | In vivo pharmacokinetic study | A 4.79-fold increase in oral bioavailability of RLN equated to RLN suspension | [136] |
| Raloxifene (RLX) | Osteoporosis | In vivo pharmacokinetic study | 3.19-fold enhancement in oral bioavailability of RLX in comparison to free RLX suspension | [137] |
| Fenofibrate | Antihyperlipidemic | In vivo pharmacokinetic study | Four times increase in oral bioavailability | [138] |
| Transferulic acid (TFA) | Antioxidative, anti-inflammatory, and cardioprotective | In vivo pharmacokinetic study | Augmented oral bioavailability than TFA-SLNs | [139] |
| Ticagrelor (TGL) | Antiplatelet activity | In vivo pharmacokinetic/pharmacodynamic study | The oral bioavailability of TGL-NLC was augmented by 254.99% in comparison to raw TGL | [140] |
|
